Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
Novartis MF59 adjuvanted cell culture-based vaccine shows strong immune response in A(H1N1) clinical trials
Novartis, 09/04/09
A pilot trial of Novartis adjuvanted cell culture–based A(H1N1) vaccine[1] indicates that the "swine flu" vaccine elicited a strong immune response and was well tolerated. The trial was run by the UK's University of Leicester and University Hospitals of Leicester. The vaccine, to be called Celtura, was tested with 100 healthy volunteers, aged between 18 and 50.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Second Pivotal Phase III Study of Gileads Darusentan for Resistant Hypertension Misses Primary Endpoints
Gilead, 12/15/09
Annual Progression of Coronary Calcification in Trials of Preventive Therapies
Archives of Internal Medicine, 12/15/09
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years
The Lancet, 12/15/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


